MedTrace Logo

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2023-08-31

No results posted yet for this study

Summary

When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other. The purpose of this study is to help determine if a drug called patiromer (already approved by the FDA) can help lower potassium levels while patients are in the emergency department.

Conditions

  • Hyperkalemia

Interventions

DRUG

Patiromer Powder for Oral Suspension [Veltassa]

Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink

DRUG

Placebo

Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink

Sponsors & Collaborators

  • Comprehensive Research Associates

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-08
Primary Completion
2023-03-09
Completion
2023-06-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04443608 on ClinicalTrials.gov